Published in Cancer Weekly, February 10th, 1997
With the initiation of these trials, the company has four related immunotherapeutic vaccines in clinical studies for melanoma, the first of which entered Phase I clinical trials in June 1996. All of the products are based on Therion's recombinant poxvirus vector technology.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.